A pilot study of memantine effects on protracted withdrawal (syndrome of anhedonia) in heroin addicts

Addictive Disorders and their Treatment

Volumn 1, Issue 4, 2002, Pages 143-146

  Krupitsky, Evgeny M ^a   Masalov, D V ^a   Burakov, A M ^a   Didenko, T Y ^a   Romanova, T N ^a   Bespalov, A Y ^a   Neznanova, O N ^a   Grinenko, N I ^a   Grinenko, A Y ^a   Slavina, T Y ^a   Tcheremissine, O V ^b   Zvartau, E E ^a  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Heroin addiction; Memantine; Syndrome of anhedonia; Treatment

Indexed keywords

AMITRIPTYLINE; MEMANTINE; PLACEBO;

ANHEDONIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEROIN DEPENDENCE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT COUNSELING; PILOT STUDY; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 11244332576     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132576-200211000-00006     Document Type: Article

References (11)

1. Krupitsky EM, Burakov AM, Romanova TN, et al. The syndrome of anhedonia in recently detoxified heroin addicts: assessment and treatment. In: Building International Research on Drug Abuse: Global Focus on Youth. Bethesda, MD: NIDA, 1998;25.
2. Nunes EV, Donovan S, Brady R, et al. Evaluation and treatment of mood and anxiety disorders in opioid-dependent patients. J Psychoact Drugs 1994;26:147-153.
3. Nunes EV, Quitkin FM, Donovan SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders. Arch Gen Psychiatry 1998;55:153-160.
4. Bespalov AY, Zvartau EE. Neuropsychopharmacology of NMDA Antagonists. St. Petersburg, Russia: Nevskii Dialekt, 2000 (in Russian).
5. Bisaga A, Corner SD, Ward AS, et al. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 2001; 157:1-10.
6. Akatinol Memantine. Frankfurt/Main, Germany: MERZ Pharma, 1992.
7. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drugs News Prospect 1998;1 1:523-569.
8. Zung WWK. The depression status inventoIy an adjunct to the self-rating depression scale. J Clin Psychol 1972;28:539-548.
9. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-trait Anxiety Inventory. Palo Alto, CA: Consulting Press, 1970.
10. Berman RM, Capellio A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-354.
11. Krystal JH, D'Souza CD, Petrakis IL, et al. NMDA antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999;7:125-143.